Book traversal links for Annex 3. Costing considerations for programmatic management of TB preventive treatment
When preparing a budget for PMTPT, the following considerations need to be made given that these are major cost determinants:
• Estimated burden
– Populations of each target group (People with HIV, contacts, clinical risk groups, other risk groups)
– Number of households and other sites (health facilities, ARV centres) to be covered for expansion of TPT activities
• Investigation of target populations
– Test for TB infection (TST/IGRA) as per national policy (such as test equipment general supplies, procurement fees for supplies, specimen collection and transport)
– Access to chest radiography services as per national policy (such as free vouchers for individuals, outsourcing chest radiography services to private providers)
– Referral for investigation (such as travel support for contacts, specimen collection and transportation)
• Human resources
‒ Hiring additional personnel/incentives for community workers or volunteers
‒ Contact investigation
▪ Transport of health care workers to
▪ Transport of contacts to facilities for TB screening, investigation and TPT
‒ TPT provision and follow-up
‒ Laboratory work
‒ Supervision and monitoring
‒ Drug distribution and management
‒ Capacity building and support
▪ Training for health care workers at different levels
▪ Job-aids
• TB preventive treatment
– Costs of medications for the regimens for different at-risk populations
– Procurement (such as freight, procurement fees, warehousing, repacking)
– Additional drug costs (such as buffer stock, procurement of supportive medicines like vitamin B6)
– Adherence support (such as phone calls, SMS, video communication, additional home visits)
• Demand creation
– Advocacy with policy makers and key stakeholders
– Sensitization of specialists and health care workers
– Community sensitization of TB survivors, People with HIV networks, and others
– Counselling of index patient/family counselling
– Health education material for at-risk populations and their family
• Monitoring and evaluation
‒ Data system(s) to aim for electronic tools for recording and reporting
‒ Update existing tools or create new ones for TB and/or HIV recording to capture key data elements for programmatic indicators and clinical management (such as adverse events)